Tumor Biology

, Volume 35, Issue 10, pp 9847–9853 | Cite as

RETRACTED ARTICLE: MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9

  • Jian-Qiang Xu
  • Wei-Bin Zhang
  • Rong Wan
  • Yao-Qi Yang
Research Article


Increasing reports suggest that discovery of microRNAs (miRNAs) might provide a novel therapeutical target for human cancers, including osteosarcoma. Previous studies have shown that miR-32 was dysregulated in breast and endometrial cancer. However, its biological roles in osteosarcoma remain unclear. In the current study, we found that miR-32 was significantly down-regulated in osteosarcoma tissues, compared with the adjacent normal tissues. In vitro studies further demonstrated that miR-32 mimics were able to suppress, while its antisense oligos promoted cell proliferation in Saos-2 and U2OS cells. At the molecular level, our data further revealed that expression of Sox9 was negatively regulated by miR-32. Therefore, our results identify an important role for miR-32 in the osteosarcoma through regulating Sox9 expression.


Osteosarcoma Cell proliferation MicroRNA miR-32 Sox9 


Conflict of interest


Supplementary material

13277_2014_2229_MOESM3_ESM.jpg (82 kb)
Supplementary Fig. 1

Expression levels of PTEN in Saos-2 and U2OS cells. (A-B) Protein levels of PTEN were determined by western blot in Saos-2 (A) and U2OS (B) cells transfected with miR-32 mimics or negative controls (NC). (JPEG 81 kb)

13277_2014_2229_MOESM1_ESM.tif (140 kb)
High resolution image (TIFF 140 kb)
13277_2014_2229_MOESM4_ESM.jpg (107 kb)
Supplementary Fig. 2

Sox9 re-introduction blocks the anti-proliferative roles of miR-32 in U2OS cells. (A) Sox9 protein expression was determined by western blot in U2OS cells. Cells were pre-transfected with miR-32 mimics or negative control (NC) for 24 hr, and then transfected with lentiviruses containing Sox9 gene or empty vector (EV) for another 24 hr. (B-D) The growth curve (B), cell proliferation (BrdU, C) and invasion abilities (D) was determined in U2OS cells. *P < 0.05 **P < 0.01, ***P < 0.001 between two groups. (JPEG 107 kb)

13277_2014_2229_MOESM2_ESM.tif (435 kb)
High resolution image (TIFF 435 kb)


  1. 1.
    Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin Pharmacol. 2014;16C:15–23.CrossRefGoogle Scholar
  3. 3.
    Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14:535–48.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475–88.CrossRefPubMedGoogle Scholar
  5. 5.
    Miao J, Wu S, Peng Z, et al. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol. 2013;34(4):2093–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Nugent M. MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag Res. 2014;6:15–25.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wang Z, Cai H, Lin L, et al. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. Pediatr Blood Cancer. 2014;61(2):206–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68(15):6162–70.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wu W, Yang J, Feng X, et al. MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer. 2013;12:30.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wu W, Yang P, Feng X, et al. The relationship between and clinical significance of MicroRNA-32 and phosphatase and tensin homologue expression in colorectal cancer. Gene Chromosome Cancer. 2013;52(12):1133–40.CrossRefGoogle Scholar
  11. 11.
    Zhang J, Kuai X, Song M, et al. microRNA-32 inhibits the proliferation and invasion of the SGC-7901 gastric cancer cell line in vitro. Oncol Lett. 2014;7(1):270–4.PubMedGoogle Scholar
  12. 12.
    Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle. 2007;6(9):1001–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6(6):567–78.CrossRefPubMedGoogle Scholar
  14. 14.
    Panda DK, Miao D, Lefebvre V, et al. The transcription factor SOX9 regulates cell cycle and differentiation genes in chondrocytic CFK2 cells. J Biol Chem. 2001;276(44):41229–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Saegusa M, Hashimura M, Suzuki E, et al. Transcriptional up-regulation of Sox9 by NF-κB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway. Am J Pathol. 2012;181(2):684–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Wegner M. All purpose Sox: the many roles of Sox proteins in gene expression. Int J Biochem Cell Biol. 2009;42:381–90.CrossRefPubMedGoogle Scholar
  17. 17.
    Matheu A, Collado M, Wise C, et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012;72(5):1301–15.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Akiyama H, Chaboissier MC, Martin JF, et al. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2813–28.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kordes U, Hagel C. Expression of SOX9 and SOX10 in central neuroepithelial tumor. J Neurooncol. 2006;80:151–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Jiang SS, Fang WT, Hou YH, et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 2010;16:4363–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang H, Leav I, Ibaragi S, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68:1625–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Bastide P, Darido C, Pannequin J, et al. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol. 2007;178(4):635–48.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cheung M, Chaboissier MC, Mynett A, et al. The transcriptional control of trunk neural crest induction, survival, and delamination. Dev Cell. 2005;8:179–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhu H, Tang J, Tang M, Cai H. Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis. Diagn Pathol. 2013;8(1):183.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rani SB, Rathod SS, Karthik S, et al. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol. 2013;15(10):1302–16.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lee S, Yoon DS, Paik S, et al. MicroRNA-495 inhibits chondrogenic differentiation in human mesenchymal stem cells by targeting Sox9. Stem Cells Dev. 2014 Mar 24.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Jian-Qiang Xu
    • 1
  • Wei-Bin Zhang
    • 1
  • Rong Wan
    • 1
  • Yao-Qi Yang
    • 1
  1. 1.Department of Orthopaedics, Ruijin Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina

Personalised recommendations